A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer

• Status: Completed
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study was designed to find out how effective and safe GW786034, is in the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer that has not responded to standard treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline

Criteria

Inclusion criteria:

• Confirmed diagnosis of epithelial ovarian, fallopian tube or primary peritoneal carcinoma.

• Has received one prior platinum-based chemotherapy regimen(cisplatin,carboplatin, or oxaliplatin).

• Has psychological, familial, sociological or geographical condition that does not permit compliance with the protocol.

• Is on a specifically prohibited medication or requires these medications during treatment with GW786034.

Exclusion criteria:

• Has had any surgery, chemotherapy, hormonal therapy, biologic, immunotherapy, or radiotherapy with in the last 28 days and has not recovered from such prior therapy.

• Poorly controlled hypertension(systolic 140mmHg or higher or Diastolic 90mmHg or higher).

• Currently taking warfarin.

• Low molecular weight heparin and low-dose warfarin(1mg per day)is permitted.